Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 51 - 100 out of 106,113

Document Document Title
WO/2015/115509A1
The purpose of the present invention is to provide a therapeutic or prophylactic agent for multiple sclerosis, which contains a non-steroid low-molecular-weight compound as an active ingredient. The present invention provides a therapeut...  
WO/2015/115898A1
The invention pertains to the use of (i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof, and (ii) a lipid fraction comprising at least one of docosahexaenoic acid (22:6; DHA), eicosapentaeno...  
WO/2015/113452A1
The present invention relates to novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, to compositions containing them and to their use in the treatment of or prevention of diseases characterized by LRRK2 k...  
WO/2015/115673A1
The present invention provides compounds represented by formula (I), pharmaceutically acceptable salts thereof, N-oxides thereof, solvates thereof or prodrugs thereof (wherein the characters are as defined in the description). The compou...  
WO/2015/116923A1
Isoindoline sigma-2 receptor antagonist compounds, pharmaceutical compositions comprising such compounds, and methods for inhibiting Abeta- associated synapse loss or synaptic dysfunction in neuronal cells, modulating an Abeta-associated...  
WO/2015/114395A1
The invention relates to an improved process for the preparation of pharmaceutical active ingredients and also to high purity salts and pharmaceutical compositions prepared by said process. More particularly the invention relates to an e...  
WO/2015/114308A1
The present invention provides the steroidal compound3-ethynyl-3- hydroxyandrostan-17-one oxime,or a pharmaceutically acceptable saltthereof,for usein treatment ofhepaticencephalopathy.  
WO/2015/115899A1
The invention pertains to the use of one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof in the manufacture of a composition for treating, preventing or reducing the risk of occurrence of white m...  
WO/2015/113451A1
Provided are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases characterized by LRRK2 kinase activity, for exampl...  
WO/2015/115885A1
The invention pertains to the use of one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof in the manufacture of a composition for treating, preventing or reducing the risk of occurrence of white m...  
WO/2015/115332A1
 A human antibody including an H chain complementarity determining region comprising an amino acid sequence shown by SEQ ID NOS: 1-3 and an L chain complementarity determining region comprising an amino acid sequence shown by SEQ ID NO...  
WO/2015/117094A1
In alternative embodiments the invention provides methods for synthesizing AB-007 (also called loxistatin, E64d, EST or ((2S,3S)-trans-epoxysuccinyl-L-leucyl-amido-3-methylbutane ethyl ester) and its acid form E64c (loxistatin acid), and...  
WO/2015/115886A1
The invention pertains to the use of (i) one or more of uridine and cytidine, or salts, phosphates, acyl derivatives or esters thereof, and (ii) a lipid fraction comprising at least one of docosahexaenoic acid (22:6; DHA), eicosapentaeno...  
WO/2015/116663A1
The present invention relates to certain heteroaryl amide compounds, pharmaceutical compositions containing them, and methods of using them, including methods for preventing, reversing, slowing, or inhibiting protein aggregation, and met...  
WO/2015/112369A1
Embodiments of the present invention relate to novel cytochrome P450 inhibitors and pharmaceutical compositions thereof having a disease-modifying action in the treatment of diseases associated with the overproduction of Cortisol that in...  
WO/2015/110589A1
The present invention concerns the field of ion channels, and in particular relates to peptides which are suitable for use in the treatment of conditions where the L-type calcium channel (LTCC) density and function is altered. LTCCs are ...  
WO/2015/112547A1
Methods of treating neuroinflammation by administration of a selective protein C activator, such as recombinant human WE thrombin and optionally one or more of its cofactors are disclosed. Also disclosed are pharmaceutical compositions f...  
WO/2015/110263A1
The present invention relates to novel compounds that can be employed in the diagnosis, treatment, alleviation or prevention of a group of disorders and abnormalities associated with amyloid proteins and amyloid-like proteins, such as Al...  
WO/2015/110848A1
Compounds of formula (I) wherein R1, R2 are independently selected from hydrogen and Cu alkyl; R3 is hydrogen or C1-4 alkyl group which is unsubstituted or substituted by phenyl, pyridyl, or amino optionally substituted by C1-4 alkyl; R4...  
WO/2015/110435A1
The present invention relates to combinations comprising a positive allosteric modulator ("PAM") of metabotropic glutamatergic receptor subtype 2 ("mGluR2") or a pharmaceutically acceptable salt or a solvate thereof, or an orthosteric ag...  
WO/2015/113057A1
Compounds (I), processes for their preparation, pharmaceutical compositions containing such compounds and their use in treating therapeutic conditions, in particular conditions mediated by the action of ligands on the FP, DP, EP1, EP4, I...  
WO/2015/109377A1
The present invention relates to a new efficient and industrially feasible process for the preparation of the commercial crystalline forms of donepezil hydrochloride Form I and III, with high purity and in a selective manner. This invent...  
WO/2015/110271A1
The present invention relates to diazabicyclo[4.3.1 ]decane derivatives (I), pharmaceutically acceptable salts of these compounds and pharmaceutical compositions containing at least one of these compounds together with pharmaceutically a...  
WO/2015/112724A1
The present invention includes compositions and methods for treating a human subject in need of treatment for acute cognitive dysfunction, comprising administering to the human subject an effective dose of N-acetylcysteine amide (NACA), ...  
WO/2015/112715A1
The present invention includes compositions and methods for treating a human subject in need of treatment for traumatic brain injury or neurological damage resulting from exposure to one or more low-energy impacts, comprising administeri...  
WO/2015/110800A1
The present invention relates to an herbal composition and its use for modifying animal behavior. The invention also refers to the administration of said herbal composition by spraying or air diffusion to non-human mammals, including cat...  
WO/2015/111602A1
Provided are: a method for producing adult oligodendrocyte-type-2 astrocyte progenitor cells from proliferative oligodendrocyte-type-2 astrocyte progenitor cells; and a pharmaceutical composition having as an effectivecomponent thereof a...  
WO/2015/109666A1
Disclosed are an ester group-containing aromatic propionamide compound, and a preparation method therefor and uses thereof, and provides a chemical structure formula of the new ester group-containing aromatic propionamide compound. The c...  
WO/2015/109935A1
The invention generally relates to compounds of formula (I) with neural protective effect, and preparation and uses thereof. The compounds have multiple mechanisms or functions, for example, inhibition of monoamine oxidase and cholineste...  
WO/2015/108449A1
The invention relates to a pharmaceutical agent exhibiting mixed nootropic properties with a broad range of activity, having an effect on a gamma-aminobutyric acid (GABA) system, and can be used in medicine, in psychoneurological prac...  
WO/2015/109215A1
This disclosure relates to pharmaceutical compositions useful for inhibiting the progression of urea cycle disorders and neurodegenerative disorders, such as Parkinson's disease, Alzheimer's disease, and multiple sclerosis. The pharmaceu...  
WO/2015/108985A1
Disclosed are compositions and methods for the treatment of a subject having an autism spectrum disorder. The disclosed compositions may contain racemic ketamine or S-ketamine. The disclosed methods of administering the compositions incl...  
WO/2015/107057A1
The present invention provides a new synthetic process for the production of 1-(2-((2,4- dimethylphenyl)thio)phenyl)piperazine (vortioxetine), a drug for the treatment of depression and anxiety, which is conducted via (2-(piperazine-1-yl...  
WO/2015/107472A1
Processes for preparing oxymorphone are provided. Said processes encompass a step which is a hydrogenation of an 14-hydroxymorphinone salt in the presence of trifluoroacetic acid and/or a glycol.  
WO/2015/108728A1
One embodiment of the invention provides a method for administering tasimelteon to a human patient that comprises orally administering an effective dose of tasimelteon under fasted conditions. Fasted conditions may comprise administering...  
WO/2015/107196A1
The present invention relates to the use of thalidomide or analogs thereof for preventing neurologic disorders induced by brain irradiation.  
WO/2015/108136A1
The present invention provides: a novel α-substituted glycinamide derivative or a pharmacologically acceptable salt thereof; a pharmaceutical composition containing the compound or the pharmacologically acceptable salt; and a use of the...  
WO/2015/109037A1
The invention provides enantiopure deuterium- enriched pioglitazone, pharmaceutical compositions, and methods of treating neurological disorders, cancer, respiratory disorders, metabolic disorders, and other disorders using enantiopure d...  
WO/2015/106641A1
The present invention provides an anti-human proBDNF monoclonal antibody, and uses thereof in pains. Specifically, the present invention provides uses of antibody polypeptide of tenth to 128th amino acid in a specific recognition pro-BDN...  
WO/2015/108372A1
The present invention relates to: a composition for preventing, alleviating or treating neurological disorders caused by excitotoxicity or synaptic dysfunction; and a method for preventing or treating neurological disorders by using the ...  
WO/2015/107471A1
Processes for preparing oxycodone are provided. Said processes encompass a step which is a hydrogenation of an 14-hydroxycodeinone salt in the presence of trifluoroacetic acid and/or a glycol.  
WO/2015/107182A1
The present invention relates to activated neurotensin, pharmaceutical compositions comprising the same, and the uses thereof. The compounds and compositions of the invention may be used e.g., to reduce body temperature, attenuate or hal...  
WO/2015/107053A1
The present invention relates to compounds of the general formula I wherein Het is oxazole-5-yl, pyridin-4-yl, or pyrazol-4-yl; R1/ R2 are, independently from each other, hydrogen, lower alkyl, lower alkoxy, or halogen; W is -CH2- or -CH...  
WO/2015/107170A1
The present invention relates to the field of molecular biochemistry and medicine, and in particular to ligands comprising modified amino acid residues, targeting the amyloid-β peptide associated with Alzheimer's disease for prevention ...  
WO/2015/106394A1
Disclosed are a grape seed polyphenol extract and a use thereof in preparing drugs for treating Alzheimer's disease, wherein the grape seed polyphenol extract is mainly prepared by membrane separation technology and comprises catechin, e...  
WO/2015/108355A1
The present invention relates to a novel glyceryl phosphoryl choline crystal and a preparation method therefor. With respect to the preparation of the glyceryl phosphoryl choline crystal of the present invention, a novel crystal can be o...  
WO/2015/108014A1
Provided are a catecholamine production accelerator comprising a natural product as an active ingredient, a therapeutic and preventive agent for diseases caused by catecholamine deficiency, and a therapeutic and preventive food compositi...  
WO/2015/105772A1
The disclosure generally relates to compounds of formula (I), including their salts, as well as compositions and methods of using the compounds. The compounds are ligands of the NR2B receptor and may be useful for the treatment of variou...  
WO/2015/105201A1
The present invention provides a method of inducing microglia cells from blood cells, comprising culturing the blood cells in the presence of interleukin-34 (IL-34) and granulocyte-macrophage colony stimulating factor (GM-CSF).  
WO/2015/104271A1
The present invention relates to compounds of formula (I) wherein Y is C-R1; R1 is hydrogen or halogen; R1 is hydrogen or halogen; R2 is hydrogen, lower alkyl or phenyl,; R4 is hydrogen or lower alkyl; or R2 and R4 may form together with...  

Matches 51 - 100 out of 106,113